Literature DB >> 11448060

Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion.

S D Konduri1, A Tasiou, N Chandrasekar, G L Nicolson, J S Rao.   

Abstract

Human tissue factor pathway inhibitor-2 (TFPI-2), also known as placental protein (PP5) and matrix-associated serine protease inhibitor (MSPI), is a 32-kDa extracellular matrix (ECM) protein consisting of three tandomly arranged Kunitz-type domains that inhibits plasmin, trypsin, chymotrypsin, cathepsin G and plasma kallikrein but not urokinase and tissue-type plasminogen activators or thrombin. Earlier studies in our laboratory revealed that the production of TFPI-2 is reduced or absent during the tumor progression of human gliomas. In the present study, we investigated the role of TFPI-2 in the invasiveness of the amelanotic melanoma cell line C-32. We stably transfected C-32 cells with a vector capable of expressing TFPI-2 in a sense orientation (0.7 kb). TFPI-2 protein production was then determined by western blotting and the mRNA level by northern blotting in parental and stably transfected (vector and sense) clones. The levels of TFPI-2 protein and mRNA were significantly higher in the sense clones, but neither was detected in parental and vector control clones. In addition, in vitro Matrigel invasion/migration assays revealed that the invasive behavior of sense clones was inhibited compared with the behavior of parental and vector clones. This is the first study to show that the upregulation of TFPI-2 plays a significant role in reducing the invasive behavior of human amelanotic melanomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11448060     DOI: 10.1023/a:1011085820250

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  41 in total

1.  Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor.

Authors:  E G Fischer; M Riewald; H Y Huang; Y Miyagi; Y Kubota; B M Mueller; W Ruf
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Localization of tissue factor in actin-filament-rich membrane areas of epithelial cells.

Authors:  M Müller; S Albrecht; F Gölfert; A Hofer; R H Funk; V Magdolen; C Flössel; T Luther
Journal:  Exp Cell Res       Date:  1999-04-10       Impact factor: 3.905

4.  Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2.

Authors:  M Iino; D C Foster; W Kisiel
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-01       Impact factor: 8.311

5.  Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.

Authors:  V Ollivier; S Bentolila; J Chabbat; J Hakim; D de Prost
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

6.  Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.

Authors:  B M Mueller; W Ruf
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

7.  Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo.

Authors:  M Yamamoto; R Sawaya; S Mohanam; A K Bindal; J M Bruner; K Oka; V H Rao; M Tomonaga; G L Nicolson; J S Rao
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

8.  Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.

Authors:  R W Werling; L R Zacharski; W Kisiel; S P Bajaj; V A Memoli; S M Rousseau
Journal:  Thromb Haemost       Date:  1993-04-01       Impact factor: 5.249

9.  Expression of tissue factor correlates with grade of malignancy in human glioma.

Authors:  K Hamada; J Kuratsu; Y Saitoh; H Takeshima; T Nishi; Y Ushio
Journal:  Cancer       Date:  1996-05-01       Impact factor: 6.860

10.  Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.

Authors:  D T Eitzman; J C Krauss; T Shen; J Cui
Journal:  Blood       Date:  1996-06-01       Impact factor: 22.113

View more
  9 in total

1.  CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.

Authors:  Niko Bretz; Aurelia Noske; Sascha Keller; Natalie Erbe-Hofmann; Thomas Schlange; Alexei V Salnikov; Gerd Moldenhauer; Glen Kristiansen; Peter Altevogt
Journal:  Clin Exp Metastasis       Date:  2011-10-08       Impact factor: 5.150

2.  Prognostic significance of tissue factor pathway inhibitor-2 in pancreatic carcinoma and its effect on tumor invasion and metastasis.

Authors:  Zhigang Tang; Guangyong Geng; Qiang Huang; Geliang Xu; Hejie Hu; Jiong Chen; Jiansheng Li
Journal:  Med Oncol       Date:  2009-09-10       Impact factor: 3.064

3.  Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.

Authors:  Sophie Iochmann; Claire Bléchet; Valérie Chabot; Annabelle Saulnier; Aniça Amini; Guillaume Gaud; Yves Gruel; Pascale Reverdiau
Journal:  Clin Exp Metastasis       Date:  2009-03-07       Impact factor: 5.150

4.  Tissue factor pathway inhibitor-2 inhibits the growth and invasion of hepatocellular carcinoma cells and is inactivated in human hepatocellular carcinoma.

Authors:  Yong Xu; Xiaolin Qin; Jinjing Zhou; Zhiguang Tu; Xiao Bi; Wuxian Li; Xiaoqing Fan; Yi Zhang
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

5.  Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.

Authors:  J Rollin; S Iochmann; C Bléchet; F Hubé; S Régina; S Guyétant; E Lemarié; P Reverdiau; Y Gruel
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

6.  Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer.

Authors:  Cheng Xu; Huijun Wang; Hongyu He; Fengyun Zheng; Yating Chen; Jin Zhang; Xiaoyan Lin; Duan Ma; Hongwei Zhang
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

7.  TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.

Authors:  Guillaume Gaud; Sophie Iochmann; Audrey Guillon-Munos; Benjamin Brillet; Stéphanie Petiot; Florian Seigneuret; Antoine Touzé; Nathalie Heuzé-Vourc'h; Yves Courty; Stéphanie Lerondel; Yves Gruel; Pascale Reverdiau
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

8.  MicroRNA-23a acts as an oncogene in pancreatic carcinoma by targeting TFPI-2.

Authors:  Wei Wang; Jin-Zhuo Ning; Zhi-Gang Tang; Ying He; Li-Chao Yao; Lin Ye; Lun Wu
Journal:  Exp Ther Med       Date:  2020-09-04       Impact factor: 2.447

9.  TFPI2 Promotes Perivascular Migration in an Angiotropism Model of Melanoma.

Authors:  Jing Mo; Xiulan Zhao; Wei Wang; Nan Zhao; Xueyi Dong; Yanhui Zhang; Runfen Cheng; Baocun Sun
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.